Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines …

Background Immunocompromised patients are at increased risk of severe COVID-19 and
impaired vaccine response. In this observational prospective study, we evaluated …

Background Studies have suggested incremental short-term adverse events (AE) after
repeated vaccination. In this report, we assessed occurrence and risk factors for short-term …

An attenuated humoral response to SARS-CoV-2 vaccination has been observed in some
patients with autoimmune disease, 1 2 and immunosuppressed status has been associated …

Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become
a high priority. Persons at risk of severe disease, for example, those receiving …

Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are actively carried out around the world. Several vaccines are currently …

Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV …

Background B-cell-depleting therapies increase the risk of morbidity and mortality due to
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …

Objectives The treatment for COVID-19 often utilizes immune-modulating drugs. These
drugs are also used in immune mediated inflammatory diseases (IMIDs). We performed a …

Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …